Summary of Key Points
Synthetic biology treats life as a programmable machine, using biological methods to replace petrochemical processes in the production of drugs, materials, food, and more, resulting in a greener and more precise approach. The global market is growing rapidly, expected to reach $95 billion by 2034, with China's market size estimated at approximately 142 billion yuan by 2025. In China, there have been 301 financings and 110 companies in this field, most of which are still in the early stages (pre-Series B). Financing activity peaked in 2022 before cooling down, but it is expected to pick up again in 2025, especially in the food sector. Capital is concentrated in areas such as platforms/tools and bio-based materials, with the Yangtze River Delta region leading the way. State-owned assets from Hefei have shown significant interest, and institutions like Fengrui are active in the industry. However, the industry faces challenges such as the "valley of death" between laboratory development and mass production, slow commercialization, and mismatches in capital cycles. Nevertheless, policy reforms, the entry of state-owned capital, and integration with AI are positive developments, indicating that future competition will focus on mass production capabilities.
I. Financing Trends: From Frenzy to Calmness, with the Food Sector Breaking Through in 2025
The trajectory of domestic synthetic biology financing has been akin to a rollercoaster: capital began to flow in 2021, reaching a peak in 2022 (with Tachuang Biology securing $2.1 billion in its A+ round); in 2023-2024, funding amounts were halved, with fewer large-scale investments indicating that investors are becoming more selective. In 2025, the number of financings doubled to 72, but the total amount dropped to $3.78 billion. The focus has shifted away from platform-based companies towards food and alternative protein technologies, as seen in cases like Hongmo Biology, which received investment for its breast milk oligosaccharide (HMO) products. Although the first half of 2026 seems promising, a significant portion of the funding ($1.5 billion) went to Weiyuan Synthesis' Series B round, limiting overall growth—this reflects a market shift from focusing on concepts to evaluating practical applications.
II. Application Areas: Who Is Drawing Capital? Who Will Survive in the Long Run?
The 110 companies in the industry are divided into seven main areas, with the following four attracting the most attention:
- Platforms/Tools: These have received the most funding (45%), such as Weiyuan Synthesis and Tachuang Biology, which are often referred to as "biological contract manufacturers." However, the challenge is that trying to do everything can lead to lack of specialization. Tachuang Biology's valuation exceeded 10 billion yuan in 2022, but its financing slowed down due to doubts about its commercialization path.
- Bio-based Materials: The highest-value single investment (around $100 million) has gone towards PHA (biodegradable plastics). Blue Crystal Microbiology raised $2 billion in eight rounds, but the cost of PHA remains higher than that of traditional plastics, making it dependent on policies like plastic restrictions, which have slowed down funding activity.
- Food/Alternative Proteins: This sector saw a surge in 2025, with subcategories like HMO and microbial proteins gaining popularity. Hongmo Biology was the first company in China to obtain safety approval for HMO products and has continued to attract investment. The logic behind this trend is a combination of policy changes (e.g., approval of HMO) and rising consumer demand, though consumer acceptance of synthetically produced goods still needs to be verified.
- Medicine/Pharmaceuticals: This area is less visible but more stable, with clear drug development paths and defined funding sources (hospitals/pharmaceutical companies). For example, Xiushi Biology is developing peptide drugs using biological methods, though most of its efforts are at the "tool" level, with original innovative drugs still in the early stages.
III. Where Does the Money Come From? Fengrui Leads, with State-Owned Capital Playing a Patient Role
- Institutional Investors: Fengrui Capital leads the way with 15 investments, having invested in leading companies like Blue Crystal Microbiology and Ketaiya Biology. Sequoia China has also made moves in this area, such as through its investment in Microstructure Workshop.
- State-Owned Capital: State-owned institutions such as Henan Investment and Hefei Jian Tou are actively participating, with Hefei adopting a new model that combines state-led investment with industry collaboration, as seen in their support for Hongmo Biology. This is because synthetic biology is considered a strategic industry, supported by policies like the 2025 Biosafety Law, which classifies synthetic products for regulation.
- **Industrial Capital (CVC): Investors like Country Garden and Tencent have only made limited investments, as synthetic biology companies are still in the pilot or mass production phases, lacking the necessary supply chain integration.
IV. The Industry's Critical Moment: From Laboratory to Mass Production—Who Will Survive?
The biggest challenge in synthetic biology is transitioning from initial research to large-scale production:
1. Scalability: Lab-scale production is feasible, but scaling up to ton levels poses difficulties due to unstable strains, low yields, and high purification costs, leading to a high failure rate.
2. Slow Commercialization: Medicines require clinical trials that can take years or even decades; materials must compete with petrochemical products on cost; food products need to convince consumers of their benefits. None of these paths are easy.
3. Capital Mismatch: VC funds typically have a seven-to-eight-year maturity period, while synthetic biology product development takes five to ten years. The investments made in 2021-2022 are now facing exit pressures, making it difficult for companies to secure further funding if they cannot achieve mass production.
However, there are positive developments: demand for food products based on synthetic biology is increasing, and state-owned capital is providing patient funding. Integration with AI (e.g., using AI to design strains) can accelerate the development process. In the future, only companies that can successfully transition their laboratory results to mass production will be able to attract investment.
Conclusion
Synthetic biology is a promising field, but it is still in its early stages of development. Financing trends indicate that the market has shifted from focusing on ideas to evaluating practical outcomes. Those companies that can solve the challenges of mass production and bring products to market will have the upper hand. For consumers, this may mean seeing more synthetically produced foods (e.g., HMO-infused formulas) and biodegradable plastics in the future. However, there is still a long way to go before synthetic biology can truly replace petrochemical products.